{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:19:04Z","timestamp":1790651944273,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals","doi-asserted-by":"publisher","award":["VEO-000059"],"award-info":[{"award-number":["VEO-000059"]}],"id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals","doi-asserted-by":"publisher","award":["VEO-000059"],"award-info":[{"award-number":["VEO-000059"]}],"id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals","doi-asserted-by":"publisher","award":["VEO-000059"],"award-info":[{"award-number":["VEO-000059"]}],"id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals","doi-asserted-by":"publisher","award":["VEO-000059"],"award-info":[{"award-number":["VEO-000059"]}],"id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals","doi-asserted-by":"publisher","award":["VEO-000059"],"award-info":[{"award-number":["VEO-000059"]}],"id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals","doi-asserted-by":"publisher","award":["VEO-000059"],"award-info":[{"award-number":["VEO-000059"]}],"id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The risk of herpes zoster (HZ) increases with age and in immunocompromised (IC) patients. Recombinant zoster vaccine (RZV) is currently recommended in Canada for people aged\u2009\u2265\u200950\u00a0years. The objectives of the current study were to evaluate the cost-effectiveness and public health impact of RZV versus no HZ vaccination in select Canadian IC adult populations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The ZOster ecoNomic Analysis ImmunoCompromised (ZONA IC) model followed a base-case cohort of 1600 patients with hematopoietic stem-cell transplant (HSCT) from a starting age of 55\u00a0years, who maintained IC status for 5\u00a0years, from a societal perspective. Scenario analyses were conducted for patients with breast cancer, renal transplant, human immunodeficiency virus (HIV), and Hodgkin lymphoma. These probabilistic analyses used a life-long time horizon and discount rates of 1.5% for costs and quality-adjusted life-years (QALYs). First-dose coverage was assumed to be 60% and second-dose completion 100%. Deterministic one-way sensitivity analysis for the base case was performed. Costs are reported in 2022 Canadian dollars, with an assumed cost-effectiveness threshold of $50,000 per QALY gained.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In the base-case analysis (HSCT), it was estimated that RZV would prevent medians of 116 HZ and 27 postherpetic neuralgia (PHN) cases, respectively versus no HZ vaccination. Estimated median numbers needed to vaccinate were 8 and 35 to avoid one HZ and one PHN case, respectively. The median incremental cost-effectiveness ratio (ICER) was $22,648 per QALY gained and was most sensitive to assumptions of HZ incidence, direct medical costs for unvaccinated HZ without PHN, and RZV efficacy against PHN. In other IC populations, estimated median ICERs were $24,328 (breast cancer), $27,237 (renal transplant), $67,207 (HIV), and $81,470 (Hodgkin lymphoma).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>RZV in Canada improves public health outcomes and is likely cost-effective for several IC conditions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s12913-025-12550-x","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T08:32:00Z","timestamp":1745569920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness and public health impact of recombinant zoster vaccine versus no herpes zoster vaccination in selected populations of immunocompromised adults in Canada"],"prefix":"10.1186","volume":"25","author":[{"given":"Sydney","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Carrico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dessi","family":"Loukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"12550_CR1","unstructured":"Government of Canada. Herpes zoster (shingles) vaccine: Canadian immunization guide. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-8-herpes-zoster-(shingles)-vaccine.html. Accessed 27 Apr 2023."},{"issue":"3","key":"12550_CR2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4161\/hv.4.3.5686","volume":"4","author":"M Brisson","year":"2008","unstructured":"Brisson M, Pellissier JM, Camden S, Quach C, De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin. 2008;4(3):238\u201345.","journal-title":"Hum Vaccin"},{"issue":"1","key":"12550_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40121-021-00567-8","volume":"11","author":"D Curran","year":"2022","unstructured":"Curran D, Callegaro A, Fahrbach K, Neupane B, Vroling H, van Oorschot D, et al. Meta-regression of herpes zoster incidence worldwide. Infect Dis Ther. 2022;11(1):389\u2013403.","journal-title":"Infect Dis Ther"},{"issue":"7","key":"12550_CR4","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1093\/cid\/ciz1090","volume":"71","author":"SL McKay","year":"2020","unstructured":"McKay SL, Guo A, Pergam SA, Dooling K. Herpes zoster risk in immunocompromised adults in the United States: a systematic review. Clin Infect Dis. 2020;71(7):e125\u201334.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"12550_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s15010-013-0550-8","volume":"42","author":"SY Chen","year":"2014","unstructured":"Chen SY, Suaya JA, Li Q, Galindo CM, Misurski D, Burstin S, et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014;42(2):325\u201334.","journal-title":"Infection"},{"issue":"2","key":"12550_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/QAI.0b013e318266cd3c","volume":"61","author":"LJ Blank","year":"2012","unstructured":"Blank LJ, Polydefkis MJ, Moore RD, Gebo KA. Herpes zoster among persons living with HIV in the current antiretroviral therapy era. J Acquir Immune Defic Syndr. 2012;61(2):203\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"12550_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/1055-9965.EPI-12-0815","volume":"22","author":"LA Habel","year":"2013","unstructured":"Habel LA, Ray GT, Silverberg MJ, Horberg MA, Yawn BP, Castillo AL, et al. The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(1):82\u201390.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"12550_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1399-3062.2010.00547.x","volume":"13","author":"SA Pergam","year":"2011","unstructured":"Pergam SA, Forsberg CW, Boeckh MJ, Maynard C, Limaye AP, Wald A, et al. Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transpl Infect Dis. 2011;13(1):15\u201323.","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"12550_CR9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.bbmt.2016.12.620","volume":"23","author":"F Sahoo","year":"2017","unstructured":"Sahoo F, Hill JA, Xie H, Leisenring W, Yi J, Goyal S, et al. Herpes zoster in autologous hematopoietic cell transplant recipients in the era of acyclovir or valacyclovir prophylaxis and novel treatment and maintenance therapies. Biol Blood Marrow Transplant. 2017;23(3):505\u201311.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"12550_CR10","doi-asserted-by":"publisher","first-page":"787","DOI":"10.4065\/84.9.787","volume":"84","author":"BP Yawn","year":"2009","unstructured":"Yawn BP, Itzler RF, Wollan PC, Pellissier JM, Sy LS, Saddier P. Health care utilization and cost burden of herpes zoster in a community population. Mayo Clin Proc. 2009;84(9):787\u201394.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"12550_CR11","doi-asserted-by":"publisher","first-page":"e023502","DOI":"10.1136\/bmjopen-2018-023502","volume":"9","author":"D Curran","year":"2019","unstructured":"Curran D, Hunjan M, El Ghachi A, El-Hahi Y, Bianco V, Ferreira G. Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis. BMJ Open. 2019;9(8):e023502.","journal-title":"BMJ Open"},{"issue":"9","key":"12550_CR12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.14745\/ccdr.v44i09a06","volume":"44","author":"R Warrington","year":"2018","unstructured":"Warrington R, Ismail S. National Advisory Committee on Immunization (NACI). Summary of the NACI Update on herpes zoster vaccines. Can Commun Dis Rep. 2018;44(9):220\u20135.","journal-title":"Can Commun Dis Rep."},{"key":"12550_CR13","unstructured":"Minist\u00e8re de la Sant\u00e9 et des Services sociaux. Zona-SU: vaccin sous-unitaire contre le zona. https:\/\/www.msss.gouv.qc.ca\/professionnels\/vaccination\/piq-vaccins\/zona-su-vaccin-sous-unitaire-contre-le-zona\/. Accessed 13 Feb 2023."},{"issue":"2","key":"12550_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jama.2019.9053","volume":"322","author":"A Bastidas","year":"2019","unstructured":"Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, Lopez-Jimenez J, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322(2):123\u201333.","journal-title":"JAMA"},{"issue":"3","key":"12550_CR15","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/rheumatology\/keaa424","volume":"60","author":"AF Dagnew","year":"2021","unstructured":"Dagnew AF, Rausch D, Herve C, Zahaf T, Levin MJ, Schuind A, et al. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatology (Oxford). 2021;60(3):1226\u201333.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"12550_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/cid\/ciz177","volume":"70","author":"P Vink","year":"2020","unstructured":"Vink P, Ramon Torrell JM, Sanchez Fructuoso A, Kim SJ, Kim SI, Zaltzman J, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial. Clin Infect Dis. 2020;70(2):181\u201390.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"12550_CR17","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","volume":"211","author":"EM Berkowitz","year":"2015","unstructured":"Berkowitz EM, Moyle G, Stellbrink HJ, Schurmann D, Kegg S, Stoll M, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study. J Infect Dis. 2015;211(8):1279\u201387.","journal-title":"J Infect Dis"},{"issue":"9","key":"12550_CR18","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","volume":"19","author":"AF Dagnew","year":"2019","unstructured":"Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988\u20131000.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"12550_CR19","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/cncr.31909","volume":"125","author":"P Vink","year":"2019","unstructured":"Vink P, Delgado Mingorance I, Maximiano Alonso C, Rubio-Viqueira B, Jung KH, Rodriguez Moreno JF, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial. Cancer. 2019;125(8):1301\u201312.","journal-title":"Cancer"},{"issue":"5","key":"12550_CR20","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s40258-019-00491-6","volume":"17","author":"A McGirr","year":"2019","unstructured":"McGirr A, Van Oorschot D, Widenmaier R, Stokes M, Ganz ML, Jung H, et al. Public health impact and cost-effectiveness of non-live adjuvanted recombinant zoster vaccine in Canadian adults. Appl Health Econ Health Policy. 2019;17(5):723\u201332.","journal-title":"Appl Health Econ Health Policy"},{"issue":"3","key":"12550_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s41669-024-00483-w","volume":"8","author":"S George","year":"2024","unstructured":"George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, et al. Updated public health impact and cost effectiveness of recombinant zoster vaccine in canadian adults aged 50 years and older. Pharmacoecon Open. 2024;8(3):481\u201392.","journal-title":"Pharmacoecon Open"},{"issue":"2","key":"12550_CR22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jval.2022.08.003","volume":"26","author":"AJ Leidner","year":"2023","unstructured":"Leidner AJ, Anderson TC, Hong K, Ortega-Sanchez IR, Guo A, Pike J, et al. Cost-effectiveness analysis of vaccination with recombinant zoster vaccine among hematopoietic cell transplant recipients and persons with other immunocompromising conditions aged 19 to 49 years. Value Health. 2023;26(2):204\u201315.","journal-title":"Value Health"},{"issue":"6","key":"12550_CR23","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s41669-023-00438-7","volume":"7","author":"A Salem","year":"2023","unstructured":"Salem A, La EM, Curran D, Patterson BJ, Carrico J, Lorenc S, et al. Cost-effectiveness of recombinant zoster vaccine for the prevention of herpes zoster in hematopoietic stem cell transplant recipients and other immunocompromised adults in the United States. Pharmacoecon Open. 2023;7(6):975\u201385.","journal-title":"Pharmacoecon Open"},{"issue":"1","key":"12550_CR24","doi-asserted-by":"publisher","first-page":"2167907","DOI":"10.1080\/21645515.2023.2167907","volume":"19","author":"D Curran","year":"2023","unstructured":"Curran D, Patterson BJ, Carrico J, Salem A, La EM, Lorenc S, et al. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer. Hum Vaccin Immunother. 2023;19(1):2167907.","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"12550_CR25","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1080\/21645515.2017.1345399","volume":"13","author":"D Curran","year":"2017","unstructured":"Curran D, Van Oorschot D, Varghese L, Oostvogels L, Mrkvan T, Colindres R, et al. Assessment of the potential public health impact of herpes zoster vaccination in Germany. Hum Vaccin Immunother. 2017;13(10):2213\u201321.","journal-title":"Hum Vaccin Immunother"},{"issue":"33","key":"12550_CR26","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.1016\/j.vaccine.2018.07.005","volume":"36","author":"D Curran","year":"2018","unstructured":"Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, Carrico J, et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018;36(33):5037\u201345.","journal-title":"Vaccine"},{"issue":"2","key":"12550_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s13555-018-0236-3","volume":"8","author":"D Watanabe","year":"2018","unstructured":"Watanabe D, Mizukami A, Holl K, Curran D, Van Oorschot D, Varghese L, et al. The potential public health impact of herpes zoster vaccination of people aged \u2265 50 years in Japan: results of a Markov model analysis. Dermatol Ther (Heidelb). 2018;8(2):269\u201384.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"12550_CR28","doi-asserted-by":"publisher","first-page":"e025553","DOI":"10.1136\/bmjopen-2018-025553","volume":"9","author":"DAM van Oorschot","year":"2019","unstructured":"van Oorschot DAM, Hunjan M, Bracke B, Lorenc S, Curran D, Starkie-Camejo H. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme. BMJ Open. 2019;9(5):e025553.","journal-title":"BMJ Open"},{"issue":"2","key":"12550_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s13555-019-0291-4","volume":"9","author":"M Shiragami","year":"2019","unstructured":"Shiragami M, Mizukami A, Kaise T, Curran D, Van Oorschot D, Bracke B, et al. Cost-effectiveness of the adjuvant recombinant zoster vaccine in Japanese adults aged 65 years and older. Dermatol Ther (Heidelb). 2019;9(2):281\u201397.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"12550_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/21645515.2019.1657753","volume":"16","author":"A Volpi","year":"2020","unstructured":"Volpi A, Boccalini S, Dari S, Clarke C, Curran D, Loiacono I, et al. The potential public health impact of herpes zoster vaccination in the 65 years of age cohort in Italy. Hum Vaccin Immunother. 2020;16(2):327\u201334.","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"12550_CR31","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1080\/21645515.2021.2002085","volume":"17","author":"D Curran","year":"2021","unstructured":"Curran D, Van Oorschot D, Matthews S, Hain J, Salem AE, Schwarz M. Long-term efficacy data for the recombinant zoster vaccine: Impact on public health and cost effectiveness in Germany. Hum Vaccin Immunother. 2021;17(12):5296\u2013303.","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"12550_CR32","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1080\/21645515.2021.1932216","volume":"17","author":"C Lee","year":"2021","unstructured":"Lee C, Jiang N, Tang H, Ye C, Yuan Y, Curran D. Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing. Hum Vaccin Immunother. 2021;17(10):3735\u201346.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"12550_CR33","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s13555-022-00744-8","volume":"12","author":"L Teng","year":"2022","unstructured":"Teng L, Mizukami A, Ng C, Giannelos N, Curran D, Sato T, et al. Cost-effectiveness analysis update of the adjuvanted recombinant zoster vaccine in Japanese older adults. Dermatol Ther (Heidelb). 2022;12(6):1447\u201367.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"12550_CR34","unstructured":"Canada's Drug and Health Technology Agency (CADTH). Guidelines for the Economic Evaluation of Health Technologies: Canada \u2014 4th Edition. https:\/\/www.cadth.ca\/guidelines-economic-evaluation-health-technologies-canada-4th-edition. Accessed 18 Jan 2023."},{"key":"12550_CR35","unstructured":"Government of Canada. National Advisory Committee on Immunization (NACI): Guidelines for the economic evaluation of vaccination programs in Canada. https:\/\/www.canada.ca\/en\/public-health\/services\/immunization\/national-advisory-committee-on-immunization-naci\/methods-process\/incorporating-economic-evidence-federal-vaccine-recommendations\/guidelines-evaluation-vaccination-programs-canada.html#Discounting. Accessed 27 Jan 2025."},{"issue":"7","key":"12550_CR36","doi-asserted-by":"publisher","first-page":"A488","DOI":"10.1016\/j.jval.2016.09.821","volume":"19","author":"EA Griffiths","year":"2016","unstructured":"Griffiths EA, Vadlamundi NK. CADTH\u2019s $50,000 cost-effectiveness threshold: fact or fiction? [abstract PHP278]. Value Health. 2016;19(7):A488.","journal-title":"Value Health"},{"issue":"10","key":"12550_CR37","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103.","journal-title":"JAMA"},{"issue":"12","key":"12550_CR38","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1016\/j.bbmt.2019.07.036","volume":"25","author":"D Curran","year":"2019","unstructured":"Curran D, Matthews S, Rowley SD, Young JH, Bastidas A, Anagnostopoulos A, et al. Recombinant zoster vaccine significantly reduces the impact on quality of life caused by herpes zoster in adult autologous hematopoietic stem cell transplant recipients: a randomized placebo-controlled trial (ZOE-HSCT). Biol Blood Marrow Transplant. 2019;25(12):2474\u201381.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"12550_CR39","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/14737167.2020.1693267","volume":"20","author":"J Eriksson","year":"2020","unstructured":"Eriksson J, Hunger M, Bourhis F, Thoren R, Popmihajlov Z, Finelli L, et al. Cost and utility in immunocompromised subjects who developed herpes zoster during the randomized V212 inactivated varicella-zoster vaccine (ZVIN) trial. Expert Rev Pharmacoecon Outcomes Res. 2020;20(6):613\u201321.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"12550_CR40","doi-asserted-by":"crossref","unstructured":"Niederwieser D, Baldomero H, Atsuta Y, Aljurf M, Seber A, Greinix HT, et al. One and half million hematopoietic stem cell transplants (HSCT). Dissemination, trends and potential to improve activity by telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT). https:\/\/ashpublications.org\/blood\/article\/134\/Supplement_1\/2035\/427903\/One-and-Half-Million-Hematopoietic-Stem-Cell. Accessed 2 Feb 2023.","DOI":"10.1182\/blood-2019-125232"},{"key":"12550_CR41","doi-asserted-by":"publisher","unstructured":"Statistics Canada. Population estimates on July 1st, by age and sex. https:\/\/doi.org\/10.25318\/1710000501-eng. Accessed 31 Mar 2022.","DOI":"10.25318\/1710000501-eng"},{"key":"12550_CR42","unstructured":"Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics. 2019. https:\/\/cdn.cancer.ca\/-\/media\/files\/research\/cancer-statistics\/2019-statistics\/canadian-cancer-statistics-2019-en.pdf. Accessed 23 Mar 2021."},{"issue":"5","key":"12550_CR43","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/BF03405246","volume":"99","author":"M Brisson","year":"2008","unstructured":"Brisson M. Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality. Can J Public Health. 2008;99(5):383\u20136.","journal-title":"Can J Public Health"},{"issue":"12","key":"12550_CR44","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2165\/11314010-000000000-00000","volume":"27","author":"M Najafzadeh","year":"2009","unstructured":"Najafzadeh M, Marra CA, Galanis E, Patrick DM. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics. 2009;27(12):991\u20131004.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"12550_CR45","first-page":"1","volume":"33","author":"BL Edgar","year":"2007","unstructured":"Edgar BL, Galanis E, Kay C, Skowronski D, Naus M, Patrick D. The burden of varicella and zoster in British Columbia 1994\u20132003: Baseline assessment prior to universal vaccination. Can Commun Dis Rep. 2007;33(11):1\u201315.","journal-title":"Can Commun Dis Rep"},{"key":"12550_CR46","unstructured":"Public Health Agency of Canada. Seasonal influenza vaccination coverage in Canada, 2019\u20132020. https:\/\/www.canada.ca\/en\/public-health\/services\/immunization-vaccines\/vaccination-coverage\/2019-2020-seasonal-influenza-flu-vaccine-coverage.html. Accessed 17 Mar 2021."},{"issue":"6","key":"12550_CR47","doi-asserted-by":"publisher","first-page":"380","DOI":"10.7326\/M18-2347","volume":"170","author":"LA Prosser","year":"2019","unstructured":"Prosser LA, Harpaz R, Rose AM, Gebremariam A, Guo A, Ortega-Sanchez IR, et al. A cost-effectiveness analysis of vaccination for prevention of herpes zoster and related complications: Input for national recommendations. Ann Intern Med. 2019;170(6):380\u20138.","journal-title":"Ann Intern Med"},{"issue":"10135","key":"12550_CR48","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/S0140-6736(18)30631-7","volume":"391","author":"DJ Winston","year":"2018","unstructured":"Winston DJ, Mullane KM, Cornely OA, Boeckh MJ, Brown JW, Pergam SA, et al. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10135):2116\u201327.","journal-title":"Lancet"},{"key":"12550_CR49","unstructured":"CanAge. Adult vaccination in Canada: Cross-country report card. 2021. https:\/\/www.canage.ca\/wp-content\/uploads\/2021\/03\/VaccineReportCard-2021-02-23-FINAL-1.pdf. Accessed 31 Mar 2021."},{"key":"12550_CR50","unstructured":"Ontario Ministry of Health. Schedule of benefits. Physician services under the Health Insurance Act. https:\/\/www.health.gov.on.ca\/en\/pro\/programs\/ohip\/sob\/physserv\/sob_master_20221201.pdf. Accessed 31 Mar 2022."},{"key":"12550_CR51","doi-asserted-by":"publisher","unstructured":"Statistics Canada. Labour force characteristics, monthly, seasonally adjusted and trend-cycle, last 5 months. https:\/\/doi.org\/10.25318\/1410028701-eng. Accessed 5 Apr 2022.","DOI":"10.25318\/1410028701-eng"},{"issue":"9","key":"12550_CR52","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.bbmt.2016.05.013","volume":"22","author":"EJ Morrison","year":"2016","unstructured":"Morrison EJ, Ehlers SL, Bronars CA, Patten CA, Brockman TA, Cerhan JR, et al. Employment status as an indicator of recovery and function one year after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(9):1690\u20135.","journal-title":"Biol Blood Marrow Transplant"},{"key":"12550_CR53","doi-asserted-by":"publisher","unstructured":"Statistics Canada. Consumer Price Index, annual average, not seasonally adjusted. https:\/\/doi.org\/10.25318\/1810000501-eng. Accessed 31 Mar 2022.","DOI":"10.25318\/1810000501-eng"},{"key":"12550_CR54","doi-asserted-by":"publisher","unstructured":"Statistics Canada. Consumer Price Index, monthly, not seasonally adjusted. https:\/\/doi.org\/10.25318\/1810000401-eng. Accessed 1 Apr 2022.","DOI":"10.25318\/1810000401-eng"},{"key":"12550_CR55","doi-asserted-by":"publisher","unstructured":"Statistics Canada. Labour productivity and related measures by business sector industry and by non-commercial activity consistent with the industry accounts. https:\/\/doi.org\/10.25318\/3610048001-eng. Accessed 5 Apr 2022.","DOI":"10.25318\/3610048001-eng"},{"key":"12550_CR56","unstructured":"Ontario Ministry of Health and Long-Term Care. Ontario Case Costing Initiative Costing Analysis Tool. Acute inpatient FY 2017\/2018 statistics by most responsible diagnosis ICD-10 Code. https:\/\/hsim.health.gov.on.ca\/hdbportal\/. Accessed 15 Jun 2021."},{"issue":"1","key":"12550_CR57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12879-017-2185-3","volume":"17","author":"KJ Friesen","year":"2017","unstructured":"Friesen KJ, Chateau D, Falk J, Alessi-Severini S, Bugden S. Cost of shingles: Population based burden of disease analysis of herpes zoster and postherpetic neuralgia. BMC Infect Dis. 2017;17(1):69.","journal-title":"BMC Infect Dis"},{"key":"12550_CR58","unstructured":"Ontario Ministry of Health and Long-Term Care. Formulary search. https:\/\/www.formulary.health.gov.on.ca\/formulary\/.\u00a0Accessed 1 Apr 2022."},{"issue":"22","key":"12550_CR59","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271\u201384.","journal-title":"N Engl J Med"},{"key":"12550_CR60","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1478-7547-8-7","volume":"8","author":"L Moore","year":"2010","unstructured":"Moore L, Remy V, Martin M, Beillat M, McGuire A. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Eff Resour Alloc. 2010;8:7.","journal-title":"Cost Eff Resour Alloc."},{"issue":"3","key":"12550_CR61","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2165\/00019053-200826030-00006","volume":"26","author":"TA Lieu","year":"2008","unstructured":"Lieu TA, Ortega-Sanchez I, Ray GT, Rusinak D, Yih WK, Choo PW, et al. Community and patient values for preventing herpes zoster. Pharmacoeconomics. 2008;26(3):235\u201349.","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"12550_CR62","doi-asserted-by":"publisher","first-page":"489","DOI":"10.7326\/M15-0093","volume":"163","author":"P Le","year":"2015","unstructured":"Le P, Rothberg MB. Cost-effectiveness of herpes zoster vaccine for persons aged 50 years. Ann Intern Med. 2015;163(7):489\u201397.","journal-title":"Ann Intern Med"},{"issue":"7","key":"12550_CR63","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/cid\/cir970","volume":"54","author":"KE Schmader","year":"2012","unstructured":"Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years. Clin Infect Dis. 2012;54(7):922\u20138.","journal-title":"Clin Infect Dis"},{"key":"12550_CR64","doi-asserted-by":"publisher","unstructured":"Statistics Canada. Mortality rates, by age group. https:\/\/doi.org\/10.25318\/1310071001-eng. Accessed 31 Mar 2022.","DOI":"10.25318\/1310071001-eng"},{"issue":"1","key":"12550_CR65","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1186\/s12879-016-1898-z","volume":"16","author":"F Marra","year":"2016","unstructured":"Marra F, Chong M, Najafzadeh M. Increasing incidence associated with herpes zoster infection in British Columbia, Canada. BMC Infect Dis. 2016;16(1):589.","journal-title":"BMC Infect Dis"},{"issue":"47","key":"12550_CR66","doi-asserted-by":"publisher","first-page":"6319","DOI":"10.1016\/j.vaccine.2013.09.018","volume":"32","author":"ML Russell","year":"2014","unstructured":"Russell ML, Dover DC, Simmonds KA, Svenson LW. Shingles in Alberta: Before and after publicly funded varicella vaccination. Vaccine. 2014;32(47):6319\u201324.","journal-title":"Vaccine"},{"issue":"47","key":"12550_CR67","doi-asserted-by":"publisher","first-page":"8580","DOI":"10.1016\/j.vaccine.2011.09.024","volume":"29","author":"P Tanuseputro","year":"2011","unstructured":"Tanuseputro P, Zagorski B, Chan KJ, Kwong JC. Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine. 2011;29(47):8580\u20134.","journal-title":"Vaccine"},{"issue":"2","key":"12550_CR68","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4065\/mcp.2010.0618","volume":"86","author":"BP Yawn","year":"2011","unstructured":"Yawn BP, Wollan PC, Kurland MJ, St Sauver JL, Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc. 2011;86(2):88\u201393.","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"12550_CR69","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.jpain.2010.02.020","volume":"11","author":"M Drolet","year":"2010","unstructured":"Drolet M, Brisson M, Schmader K, Levin M, Johnson R, Oxman M, et al. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain. 2010;11(11):1211\u201321.","journal-title":"J Pain"},{"issue":"11","key":"12550_CR70","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.4065\/82.11.1341","volume":"82","author":"BP Yawn","year":"2007","unstructured":"Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341\u20139.","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"12550_CR71","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/j.vaccine.2012.01.045","volume":"30","author":"M Drolet","year":"2012","unstructured":"Drolet M, Levin MJ, Schmader KE, Johnson R, Oxman MN, Patrick D, et al. Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine. 2012;30(12):2047\u201350.","journal-title":"Vaccine"},{"key":"12550_CR72","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-7596-1","volume-title":"Self-reported population health: An international perspective based on EQ-5D","author":"A Szende","year":"2014","unstructured":"Szende A, Janssen B, Cabases J. Self-reported population health: An international perspective based on EQ-5D. Dordrecht: Springer, Netherlands; 2014."},{"issue":"34","key":"12550_CR73","doi-asserted-by":"publisher","first-page":"E932","DOI":"10.1503\/cmaj.190274","volume":"191","author":"M Drolet","year":"2019","unstructured":"Drolet M, Zhou Z, Sauvageau C, DeWals P, Gilca V, Amini R, et al. Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study. CMAJ. 2019;191(34):E932\u20139.","journal-title":"CMAJ"},{"key":"12550_CR74","unstructured":"Canadian Institute for Health Information. Annual statistics on organ replacement in Canada. Dialysis, transplantation and donation, 2010 to 2019. https:\/\/secure.cihi.ca\/free_products\/corr-dialysis-transplantation-donation-2010-2019-snapshot-en.pdf. Accessed 23 Mar 2021."},{"key":"12550_CR75","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12879-015-0969-x","volume":"15","author":"S Patterson","year":"2015","unstructured":"Patterson S, Cescon A, Samji H, Chan K, Zhang W, Raboud J, et al. Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada. BMC Infect Dis. 2015;15:274.","journal-title":"BMC Infect Dis."},{"key":"12550_CR76","unstructured":"National Cancer Institute. Cancer Stat Facts: Hodgkin lymphoma. New cases and deaths. Percent of new cases by age group: Hodgkin lymphoma. https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html. Accessed 14 Feb 2023."},{"issue":"11","key":"12550_CR77","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019\u201332.","journal-title":"N Engl J Med"},{"issue":"22","key":"12550_CR78","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087\u201396.","journal-title":"N Engl J Med"},{"key":"12550_CR79","unstructured":"Government of Canada. Adult National Immunization Coverage Survey (aNICS): 2023 results. https:\/\/www.canada.ca\/en\/public-health\/services\/immunization-vaccines\/vaccination-coverage\/adult-national-immunization-coverage-survey-2023-results.html. Accessed 8 Jan 2025."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12550-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-12550-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12550-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:02:44Z","timestamp":1745575364000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-12550-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12550"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-12550-x","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"21 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DL, IK, CN, and DC are employed by, and holds financial equities in GSK. SG is employed by GSK. JC and KH are employed by RTI - Health Solutions and their employer received consulting fees from GSK to perform the work contributing to this research. All authors declare no other financial and non-financial relationships and activities.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"604"}}